Act now for affordable HIV treatment in Egypt, Morocco and Tunisia

Act now for affordable HIV treatment in Egypt, Morocco and Tunisia

Project

This project will focus on three target countries from MENA region: Morocco, Tunisia and Egypt. Providing these countries with access to affordable, generic ARVs is critical to addressing the large unmet need for ART. Lack of generic availability and high branded prices for key ARVs have directly translated to restricted ART coverage and/or an inability to provide the best possible regimens for patients in the three target countries. By addressing the legal and intellectual property barriers to generic market entry in the three target countries, this intervention aims to facilitate generic competition for key ARVs, which will lead to significantly lower prices. ITPC-MENA will organize national trainings on IP and access to medicines in each country to create knowledge and strengthen capacities of civil society groups. The project aims for national IP laws that are public health friendly and include all TRIPS safeguards.

Project details

Time frame
30 December 2014 - 30 December 2018
Budget
€ 120,000
Active in
Egypt, Morocco, Tunisia

Objectives

This project aims to facilitate generic competition for key ARVs, which will lead to significantly lower prices. These price reductions will then enable Morocco, Tunisia and Egypt to purchase more medicines and treat more of the patients still in need of ART. This projectwill also help ensure that these countries can afford to procure the highest-quality, WHO-recommended regimens.

Background

While the HIV epidemic in the Middle East and North Africa (MENA) is considered among the fastest growing epidemics in the world, the region registers the lowest rate of coverage of ART with less than one in eight people eligible for ART receiving it by end of 2012. This project will focus on three target countries from MENA region: Morocco, Tunisia and Egypt, which combined represent 12.000 people living with HIV. In all of these countries, HIV infections are more concentrated in stigmatized and vulnerable populations such as sex workers, injecting drug users, and men who have sex with men. Providing these countries with access to affordable, generic ARVs is critical to addressing the large unmet need for ART.

Lack of generic availability and high branded prices for key ARVs have directly translated to restricted ART coverage and/or an inability to provide the best possible regimens for patients in the three target countries.

Goals

Everyone living with HIV worldwide receives treatment
100%
Contributed within this project

Other projects within the programme

Fewer barriers to HIV and HCV medications for most affected in Kyrgyzstan

The Partnership Network Association (PNA) includes 26 non-governmental organizat...

Eliminating IP barriers to treatment in Malaysia

As the only registered organization in Malaysia consisting of PLHIV, Positive Ma...

2014 RfP - Eliminating intellectual property barriers

This project is part of 2014 RfP - Eliminating intellectual property barriers

In order to offer you the best website experience possible, this site places cookies on your computer.
Read more about our privacy policy and our cookie policy.